載入...
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
INTRODUCTION: In clinical trials, toxicity leading to discontinuation of tenofovir (TDF) is a rare occurrence (3% by two years)[1, 2]; however, in clinical practice it seems to be higher. Previous studies suggested that TDF toxicity is higher when it is co-administered with ritonavir-boosted proteas...
Na minha lista:
| 發表在: | J Int AIDS Soc |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
International AIDS Society
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4224916/ https://ncbi.nlm.nih.gov/pubmed/25394078 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.17.4.19571 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|